The stock of Verona Pharma Plc ADR (NASDAQ:VRNA) last traded at $12.04, up 0.33% from the previous session.
VRNA stock price is now -21.33% away from the 50-day moving average and -25.98% away from the 200-day moving average. The market capitalization of the company currently stands at $976.20M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
, while ‘Piper Sandler’ rates the stock as ‘Overweight’
In other news, Rickard Kathleen A., Chief Medical Officer sold 36,248 shares of the company’s stock on May 03 ’24. The stock was sold for $71,032 at an average price of $1.96. Upon completion of the transaction, the Chief Medical Officer now directly owns 2,621,552 shares in the company, valued at $31.56 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 05 ’24, Chief Medical Officer Rickard Kathleen A. sold 36,248 shares of the business’s stock. A total of $80,503 was realized by selling the stock at an average price of $2.22. This leaves the insider owning 2,731,624 shares of the company worth $32.89 million. A total of 24.11% of the company’s stock is owned by insiders.
During the past 12 months, Verona Pharma Plc ADR has had a low of $11.83 and a high of $23.07. As of last week, the company has a debt-to-equity ratio of 0.23, a current ratio of 18.40, and a quick ratio of 18.40. The fifty day moving average price for VRNA is $15.2354 and a two-hundred day moving average price translates $16.233126 for the stock.
The latest earnings results from Verona Pharma Plc ADR (NASDAQ: VRNA) was released for 2024-03-31. According to the Biotechnology Company, earnings per share came in at -0.08, beating analysts’ expectations of -0.29 by 0.21. This compares to -$0.22 EPS in the same period last year. The company reported revenue of $27.2 million for the quarter, compared to $22.2 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 22.52 percent.
